A patient death has prompted Atara Biotherapeutics to issue a voluntary hold on patient recruitment into its potentially groundbreaking phase 1 trial of the CAR-T cell therapy ATA2271 for pleural mesothelioma, an untreatable cancer.
Source: Drug Industry Daily